Bailard Inc. Sells 342 Shares of Stryker Co. (NYSE:SYK)

Bailard Inc. lowered its position in shares of Stryker Co. (NYSE:SYK) by 3.0% in the 4th quarter, Holdings Channel.com reports. The fund owned 11,095 shares of the medical technology company’s stock after selling 342 shares during the quarter. Bailard Inc.’s holdings in Stryker were worth $3,323,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in SYK. Sycomore Asset Management grew its position in Stryker by 446.8% in the 4th quarter. Sycomore Asset Management now owns 5,681 shares of the medical technology company’s stock worth $1,699,000 after purchasing an additional 4,642 shares during the period. Tokio Marine Asset Management Co. Ltd. increased its holdings in Stryker by 7.1% in the 4th quarter. Tokio Marine Asset Management Co. Ltd. now owns 8,477 shares of the medical technology company’s stock valued at $2,539,000 after acquiring an additional 561 shares during the last quarter. Atria Wealth Solutions Inc. increased its holdings in Stryker by 0.7% in the 4th quarter. Atria Wealth Solutions Inc. now owns 17,492 shares of the medical technology company’s stock valued at $5,245,000 after acquiring an additional 128 shares during the last quarter. GAMMA Investing LLC bought a new stake in Stryker in the 4th quarter valued at $345,000. Finally, Linden Thomas Advisory Services LLC increased its holdings in Stryker by 13.6% in the 4th quarter. Linden Thomas Advisory Services LLC now owns 3,310 shares of the medical technology company’s stock valued at $991,000 after acquiring an additional 395 shares during the last quarter. Institutional investors own 77.09% of the company’s stock.

Insider Buying and Selling at Stryker

In related news, Director Allan C. Golston sold 3,273 shares of Stryker stock in a transaction that occurred on Friday, February 2nd. The shares were sold at an average price of $341.00, for a total value of $1,116,093.00. Following the completion of the transaction, the director now owns 14,242 shares in the company, valued at $4,856,522. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In related news, Director Ronda E. Stryker sold 201,146 shares of Stryker stock in a transaction that occurred on Monday, February 5th. The shares were sold at an average price of $342.90, for a total value of $68,972,963.40. Following the completion of the transaction, the director now owns 3,755,128 shares in the company, valued at $1,287,633,391.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Allan C. Golston sold 3,273 shares of Stryker stock in a transaction that occurred on Friday, February 2nd. The stock was sold at an average price of $341.00, for a total transaction of $1,116,093.00. Following the completion of the transaction, the director now owns 14,242 shares of the company’s stock, valued at approximately $4,856,522. The disclosure for this sale can be found here. Insiders sold a total of 212,109 shares of company stock worth $72,845,768 over the last three months. Insiders own 5.90% of the company’s stock.

Stryker Stock Up 0.2 %

NYSE:SYK traded up $0.62 during midday trading on Thursday, reaching $337.47. 713,231 shares of the stock traded hands, compared to its average volume of 1,275,070. Stryker Co. has a 12-month low of $249.98 and a 12-month high of $361.41. The business has a 50-day moving average of $349.39 and a two-hundred day moving average of $314.24. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.97 and a current ratio of 1.58. The stock has a market capitalization of $128.40 billion, a PE ratio of 40.83, a price-to-earnings-growth ratio of 2.70 and a beta of 0.89.

Stryker (NYSE:SYK) last released its quarterly earnings data on Tuesday, January 30th. The medical technology company reported $3.46 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.27 by $0.19. Stryker had a net margin of 15.44% and a return on equity of 22.99%. The firm had revenue of $5.82 billion during the quarter, compared to analysts’ expectations of $5.60 billion. During the same period last year, the business earned $3.00 earnings per share. Stryker’s revenue was up 11.8% compared to the same quarter last year. On average, equities analysts forecast that Stryker Co. will post 11.86 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, April 30th. Shareholders of record on Friday, March 29th will be given a dividend of $0.80 per share. This represents a $3.20 dividend on an annualized basis and a dividend yield of 0.95%. The ex-dividend date is Wednesday, March 27th. Stryker’s dividend payout ratio is presently 38.79%.

Wall Street Analyst Weigh In

SYK has been the topic of a number of research reports. Truist Financial lifted their price target on shares of Stryker from $330.00 to $345.00 and gave the company a “hold” rating in a report on Wednesday, January 31st. Canaccord Genuity Group upgraded shares of Stryker from a “hold” rating to a “buy” rating and set a $360.00 target price on the stock in a report on Wednesday, January 31st. Royal Bank of Canada boosted their target price on shares of Stryker from $360.00 to $386.00 and gave the stock an “outperform” rating in a report on Monday, April 15th. StockNews.com upgraded shares of Stryker from a “hold” rating to a “buy” rating in a report on Tuesday, January 23rd. Finally, Wells Fargo & Company upped their price target on shares of Stryker from $336.00 to $364.00 and gave the company an “overweight” rating in a report on Wednesday, January 31st. Three research analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. Based on data from MarketBeat, Stryker currently has a consensus rating of “Moderate Buy” and a consensus price target of $340.67.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.